Literature DB >> 24316419

Disease severity and functional factors associated with walking performance in polyostotic fibrous dysplasia.

Scott M Paul1, Lisa R Gabor2, Scott Rudzinski3, David Giovanni4, Alison M Boyce5, Marilyn R N Kelly6, Michael T Collins7.   

Abstract

The purpose of this study was to determine the association between measures of disease severity, impairment, and ambulation ability in persons with polyostotic fibrous dysplasia (PFD). A cross-sectional sample of 81 patients (ages 5-57) with polyostotic fibrous dysplasia was evaluated as part of an ongoing study. Subjects were scored on the Skeletal Disease Burden Score (SDBS), completed a 9-minute walk test (9MW), manual muscle testing (MMT), and measurements of range of motion (ROM). Correlations between continuous variables were calculated using the Pearson correlation coefficient and ordinal variables by Spearman correlation coefficient. It was found that subjects with more severe disease walked slower than those with less skeletal disease, with the exception of the youngest subjects. Walking velocity was faster in subjects with better hip strength and range of motion and slower in those with bilateral coxa vara. Those subjects with more severe disease had less range of motion, were weaker at the hips, and more likely to have leg length discrepancy. Skeletal disease severity was associated with hip weakness, leg length discrepancy, and loss of range of motion. In most cases, findings did not differ in the presence or absence of associated endocrinopathies. Skeletal disease severity, MMT and ROM each has an impact on walking efficiency in persons with PFD. These findings suggest that treatment focused on strategies to improve or, at least, maintain hip strength and range of motion, correct leg length discrepancies and hip malalignment may help preserve ambulation ability in persons with PFD and that treatment should begin at a young age. Published by Elsevier Inc.

Entities:  

Keywords:  Ambulation; Functional measures; McCune–Albright Syndrome; Polyostotic fibrous dysplasia

Mesh:

Year:  2013        PMID: 24316419      PMCID: PMC3985279          DOI: 10.1016/j.bone.2013.11.022

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  41 in total

1.  The natural history of fibrous dysplasia. An orthopaedic, pathological, and roentgenographic study.

Authors:  W H HARRIS; H R DUDLEY; R J BARRY
Journal:  J Bone Joint Surg Am       Date:  1962-03       Impact factor: 5.284

Review 2.  Craniofacial fibrous dysplasia: an update.

Authors:  Yu-Ray Chen; Cheng-Nen Chang; Ying-Chien Tan
Journal:  Chang Gung Med J       Date:  2006 Nov-Dec

3.  Muscle strength and walking ability in diplegic cerebral palsy: implications for assessment and management.

Authors:  Nicky Thompson; Julie Stebbins; Maria Seniorou; Di Newham
Journal:  Gait Posture       Date:  2010-12-18       Impact factor: 2.840

4.  Six-minute walk test in children and adolescents.

Authors:  Ralf Geiger; Alexander Strasak; Benedikt Treml; Klaus Gasser; Axel Kleinsasser; Victoria Fischer; Harald Geiger; Alexander Loeckinger; Joerg I Stein
Journal:  J Pediatr       Date:  2007-04       Impact factor: 4.406

5.  An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone.

Authors:  Michael T Collins; Harvey Kushner; James C Reynolds; Caroline Chebli; Marilyn H Kelly; Anurag Gupta; Beth Brillante; Arabella I Leet; Mara Riminucci; Pamela Gehron Robey; Paolo Bianco; Shlomo Wientroub; Clara C Chen
Journal:  J Bone Miner Res       Date:  2004-11-16       Impact factor: 6.741

6.  Normal vision despite narrowing of the optic canal in fibrous dysplasia.

Authors:  Janice S Lee; Edmond FitzGibbon; John A Butman; Craig R Dufresne; Harvey Kushner; Shlomo Wientroub; Pamela G Robey; Michael T Collins
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

7.  Reference equations for the six-minute walk in healthy adults.

Authors:  P L Enright; D L Sherrill
Journal:  Am J Respir Crit Care Med       Date:  1998-11       Impact factor: 21.405

8.  Current approach to fibrous dysplasia of bone and McCune-Albright syndrome.

Authors:  Arabella I Leet; Michael T Collins
Journal:  J Child Orthop       Date:  2007-02-23       Impact factor: 1.548

9.  McCune-Albright syndrome.

Authors:  Claudia E Dumitrescu; Michael T Collins
Journal:  Orphanet J Rare Dis       Date:  2008-05-19       Impact factor: 4.123

10.  A novel technique based on a PNA hybridization probe and FRET principle for quantification of mutant genotype in fibrous dysplasia/McCune-Albright syndrome.

Authors:  Abdullah Karadag; Mara Riminucci; Paolo Bianco; Natasha Cherman; Sergei A Kuznetsov; Nga Nguyen; Michael T Collins; Pamela G Robey; Larry W Fisher
Journal:  Nucleic Acids Res       Date:  2004-04-19       Impact factor: 16.971

View more
  11 in total

Review 1.  Fibrous Dysplasia/McCune-Albright Syndrome: Clinical and Translational Perspectives.

Authors:  Cemre Robinson; Michael T Collins; Alison M Boyce
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

Review 2.  Fibrous dysplasia of bone: craniofacial and dental implications.

Authors:  A B Burke; M T Collins; A M Boyce
Journal:  Oral Dis       Date:  2016-09-01       Impact factor: 3.511

Review 3.  Fibrous Dysplasia of Bone and McCune-Albright Syndrome: A Bench to Bedside Review.

Authors:  Iris Hartley; Maria Zhadina; Micheal T Collins; Alison M Boyce
Journal:  Calcif Tissue Int       Date:  2019-04-29       Impact factor: 4.333

4.  Long Bone Fractures in Fibrous Dysplasia/McCune-Albright Syndrome: Prevalence, Natural History, and Risk Factors.

Authors:  Raya E S Geels; Maartje E Meier; Amanda Saikali; Roula Tsonaka; Natasha M Appelman-Dijkstra; Alison M Boyce
Journal:  J Bone Miner Res       Date:  2021-11-17       Impact factor: 6.390

Review 5.  The Clinical Spectrum of McCune-Albright Syndrome and Its Management.

Authors:  Tiahna Spencer; Kristen S Pan; Michael T Collins; Alison M Boyce
Journal:  Horm Res Paediatr       Date:  2019-12-19       Impact factor: 2.852

6.  Burosumab treatment for fibrous dysplasia.

Authors:  Anne Gladding; Vivian Szymczuk; Bethany A Auble; Alison M Boyce
Journal:  Bone       Date:  2021-05-11       Impact factor: 4.626

Review 7.  Dental-craniofacial manifestation and treatment of rare diseases.

Authors:  En Luo; Hanghang Liu; Qiucheng Zhao; Bing Shi; Qianming Chen
Journal:  Int J Oral Sci       Date:  2019-02-20       Impact factor: 6.344

Review 8.  Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium.

Authors:  Muhammad Kassim Javaid; Alison Boyce; Natasha Appelman-Dijkstra; Juling Ong; Patrizia Defabianis; Amaka Offiah; Paul Arundel; Nick Shaw; Valter Dal Pos; Ann Underhil; Deanna Portero; Lisa Heral; Anne-Marie Heegaard; Laura Masi; Fergal Monsell; Robert Stanton; Pieter Durk Sander Dijkstra; Maria Luisa Brandi; Roland Chapurlat; Neveen Agnes Therese Hamdy; Michael Terrence Collins
Journal:  Orphanet J Rare Dis       Date:  2019-06-13       Impact factor: 4.123

9.  Increasing serum alkaline phosphatase is associated with bone deformity progression for patients with polyostotic fibrous dysplasia.

Authors:  Jun Wang; Zhiye Du; Dasen Li; Rongli Yang; Taiqiang Yan; Wei Guo
Journal:  J Orthop Surg Res       Date:  2020-12-03       Impact factor: 2.359

Review 10.  Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation.

Authors:  Alison M Boyce; Michael T Collins
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.